Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
StockNews.AI · 2 hours
AI Summary
Merck KGaA has agreed to acquire Bio-Techne for $73 per share in cash, valuing the company at about $11.3 billion and delivering a 36% premium to Bio-Techne's one-month VWAP. The transaction is expected to be immediately accretive to EBITDA and sales, with EPS accretive by year three, and will broaden Merck KGaA's life-science capabilities across multi-omics, spatial biology, and advanced therapeutics.
Sentiment Rationale
The all-cash $73 offer creates an immediate value floor near the proposal price, likely pushing TECH higher toward the offer level, barring deal-approval risk or financing concerns.
Trading Thesis
BIO-Techne (TECH) should rerate toward $73 on closing optimism; risk remains until approvals.
Market-Moving
- Cash offer sets clear upside to $73, driving a near-term gap-up for TECH.
- Timeline to close by late 2026/early 2027 creates a concrete catalyst window.
- Regulatory and Bio-Techne shareholder approvals are key near-term hurdles.
Key Facts
- Merck KGaA to acquire Bio-Techne for US$73/share cash; EV US$11.3B.
- Premium of 36% to Bio-Techne's 1-month VWAP; close by late 2026 or early 2027.
- Deal is expected to be immediately accretive to EBITDA and sales; EPS accretive by year 3.
- Bio-Techne adds multi-omics, spatial biology, and integrated workflows to Merck KGaA.
- EUR 140M annual cost synergies anticipated by year 3 post-closing.
Companies Mentioned
- Merck KGaA, Darmstadt, Germany (N/A): Acquirer; aims to expand high-growth life-science platforms and realize EUR 140M synergies by year 3.
- Bio-Techne Corporation (TECH): Target; cash offer of $73 per share; board approval; potential shareholder vote; accretive earnings.
M&A
Category: M&A. Fits as a strategic combination in life-science tools that broadens reach, accelerates innovation, and drives cost synergies across discovery to manufacturing.